CVI Holdings’s Regulus Therapeutics RGLS Stock Holding History

CVI Holdings’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$716K	Sell	401,012 -1,005,238	-71%	-$2.33M	0.62%	24
2024 Q1	$4.05M	Buy	+1,406,250	New	+$2.29M	3.81%	2
2021 Q1	–	Sell	-160,772	Closed	-$2.17M	–	623
2020 Q4	$2.17M	Buy	+160,772	New	+$1.18M	0.41%	65
2020 Q2	–	Sell	-28,015	Closed	-$129K	–	75
2020 Q1	$129K	Sell	28,015 -10,582	-27%	-$92.3K	0.45%	25
2019 Q4	$344K	Buy	+38,597	New	+$268K	0.48%	19
2019 Q3	–	Sell	-45,419	Closed	-$568K	–	58
2019 Q2	$568K	Buy	+45,419	New	+$523K	0.66%	23

Other funds holding RGLS

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CVI Holdings's RGLS Position: Q2 2024 in Review

CVI Holdings reduced its Regulus Therapeutics (RGLS) stake by 71% in Q2 2024, selling an estimated $2.33M and leaving 401,012 shares worth $716K. The position accounts for 0.62% of the portfolio, ranked #24.

CVI Holdings first reported a position in RGLS in Q2 2019 and has held it in 6 quarters since. The position peaked at $4.05M in Q1 2024. 63 funds tracked by Wall St. Rank hold RGLS as of Q2 2024.

CVI Holdings held 401,012 shares of Regulus Therapeutics worth $716K as of Q2 2024.
CVI Holdings sold 1,005,238 Regulus Therapeutics shares in Q2 2024, an estimated $2.33M.
Regulus Therapeutics made up 0.62% of CVI Holdings's portfolio in Q2 2024, its #24 holding.
CVI Holdings first reported a position in Regulus Therapeutics in Q2 2019 and has held it in 6 quarters since.
CVI Holdings's Regulus Therapeutics position peaked at $4.05M in Q1 2024.
63 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2024.

Based on CVI Holdings's 13F filing for Q2 2024, filed 15 Aug 2024.